(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

If you want people to adopt it, they need to have trust. If there's no adoption, we will squander the incredible potential of many new technologies' Deputy Chief Lauren Pogue said at a press ...

The seller touts this diesel Land Rover as being “Noisy, leaky, rattly,” but says, “if you know what this is, you… ...